cyrilzakka/clinical-trials huggingface dataset:
Effects of Internet - Based Cognitive Behavioral Therapy on Sleep Problems Among Sample of Post- Menopausal

Sleep problems become more prominent with aging and worse among post-menopause than perimenopause stage. The actual causes of sleep problems are unclear. However, it occurs commonly accompanied with or in the response of seriousness of menpausal symptoms as nocturnal hot flashes, mood disorders, and obstructive sleep apnea among menopauses. The Prevalence of sleep problems is variable ranged from 11.8 -62 % based on different studies.

Cognitive-behavioral therapy (CBT) is one of the short-term form of psychotherapy, used for managing sleep problems and insomnia , an efficacious as pharmacological treatment.

As life expectancy has increased, women spend more than one-third of their lives in menopausal transition (MT) and the subsequent post menopause (PM).As a result of hormonal changes women experiences such symptoms as hot flashes, mood swings, anxiety, and sexual dysfunction that deteriorate their quality of life. Those symptoms usually begin in 45-53-year-olds and it varies in onset and severity from women to another and from country to another.

Symptoms of sleep problems include the difficulty of falling asleep, fractioned sleep, night-time awakening, the inability of resuming sleep, problems in waking up, fatigue, and daytime sleepiness that potentiate poor physical and mental quality of life.

The goal of CBT is to teach women how to modify maladaptive behaviors and thoughts that may contribute to a particular problem as sleep problems, anxious thoughts, and vasomotor symptoms

Eligibility Criteria:
Inclusion Criteria:

1. Menopaused women age between 50 and65 years
2. Able to read and write
3. Being normally ( primary ) menopause at least one year
4. Willing to give written informed consent to participate in the study.
5. Women obtaining more than 5 of the total score of the Pittsburgh Sleep Quality Index (PSQI)( that indicates poor sleep )
6. Have smartphone with internet access (WhatsApp) application

Exclusion Criteria:

1. Has serious physical disorders or uncontrolled conditions as uncontrolled blood pressure , uncontrolled blood glucose level, on hemodialysis
2. Receiving psychotropic medications, hormone replacement therapy (HRT),
3. Undergoing hysterectomy
4. Has acute or chronic surgical conditions, cancer or any other serious illness
5. Has cognitive impairments or physical handicap
6. Giving prescribed or non-prescribed medication or herbals that influencing sleep .
Home Transfusion for HEME

The purpose of the research is to assess the feasibility and acceptability of a home blood transfusion program for patients with hematologic malignancies who need blood transfusions

This feasibility study will be used to assess the feasibility and acceptability of a hospice-embedded home transfusion program to patients with hematologic malignancies. All enrolled subjects will be patients cared for at Dana Farber Cancer Institute.

This study is a single-arm study of 10 patients with advanced hematologic malignancies who have a limited life-expectancy of six months or fewer and are hospice eligible.

10 Caregivers of enrolled patients will also be invited to participate if interested.

This research study involves completing questionnaires, a brief interview, blood draws, and blood transfusions when needed.

Participants will be in the research study for up to six months.

It is expected that about 20 people will take part in this research study.

Eligibility Criteria:
Inclusion Criteria:

* Patients with advanced hematologic malignancies:

  * Diagnosis of a hematologic malignancy
  * Age ≥ 18 years
  * Receipt of primary oncologic care at DFCI (at least 2 outpatient visits in 12 months prior to enrollment)
  * Has received at least one red blood cell (RBC) or platelet transfusion since blood cancer diagnosis in the clinic or hospital setting without a serious adverse transfusion reaction
  * Physician-estimated prognosis of six months or less
  * Has an adult informal caregiver that lives in the same residence
  * Patient resides within catchment served by Care Dimensions Hospice
* Caregivers:

  * Identified informal caregiver of enrolled patient with hematologic malignancy
  * Age ≥ 18 years

Exclusion Criteria:

* Patients

  * Age \< 18 years
  * Does not have an identified adult informal caregiver who lives in the same residence
  * History of previous serious adverse transfusion reaction
  * Presence of decompensated congestive heart failure
* Caregiver

  * Age \< 18 years
  * Our study will exclude members of the following special populations:

    * Adults unable to consent
    * Individuals who are not yet adults (infants, children, teenagers)
    * Pregnant women
    * Prisoners
Validation of the Utility of Rare Disease Intelligence Platform

The prevention and treatment of diseases via artificial intelligence represents an ultimate goal in computational medicine. The artificial intelligence for systematic clinical application has not yet been successfully validated. Currently, the main prevention strategy for rare diseases is to build specialized care centers. However, these centers are scattered, and their coverage is insufficient, resulting in inadequate health care among a large proportion of rare disease patients. Here, the investigators use "deep learning" to create CC-Cruiser, an intelligence agent involving three functional networks: "pick-up networks" for diagnostics, "evaluation networks" for risk stratification and "strategist networks" to provide assisted treatment decisions. The investigator also establish a cloud intelligence platform for multi-hospital collaboration and conduct clinical trial and website-based study to validate its versatility.


Eligibility Criteria:
Inclusion Criteria:

* Patients who underwent ophthalmic examination of the eye and recorded their ocular information in the collaborating hospital.

Exclusion Criteria:

-
Efficacy Of Combined Nebulized Hypertonic Saline and Chest Percussion Therapy in Acute Viral Bronchiolitis

This study will examine the efficacy of combined nebulized hypertonic saline with chest percussion therapy in patients age 0 to 24 months admitted to the general inpatient pediatrics unit with acute bronchiolitis. 3% nebulized hypertonic saline treatments combined with 3 minutes of chest percussion therapy will be administered every 6 hours of patients selected for the study.


Eligibility Criteria:
Inclusion Criteria:

In order to be eligible to participate in this study (experimental arm), an individual must meet all of the following criteria:

* Age 0 to 24 months
* Admitted to the general inpatient pediatrics unit
* Has a diagnosis of acute bronchiolitis
* Receiving supplemental oxygen support

Data collected for the control arm will be obtained via retrospective chart review for patients meeting the following inclusion criteria:

* Age 0 to 24 months
* Admitted to the general inpatient pediatrics unit
* Has a diagnosis of acute bronchiolitis
* Receiving supplemental oxygen support

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

* Admitted to the pediatric intensive care unit
* Has an underlying pre-existing condition that may affect the respiratory system (includes bronchopulmonary dysplasia, reactive airways disease, asthma, restrictive lung diseases, other chronic lung diseases, etc.)
* Has other comorbid conditions upon admission that may affect the respiratory system (includes pneumonia or other bacterial or fungal lung infections, acute exacerbation of reactive airways disease, acute exacerbation of asthma, pulmonary edema, pleural effusion, etc.)
* Has an absolute contraindication to nebulized 3% hypertonic saline, for example, a history of an allergic or anaphylactic reaction
* Is receiving other respiratory treatments such as bronchodilator treatments (i.e. albuterol or levalbuterol)
* Is receiving other adjuvant therapy such as antibiotics, antivirals, glucocorticoids, corticosteroids, or diuretics

A potential study subject in the control arm via retrospective chart review who meets any of the following criteria will be excluded from this study:

* Admitted to the pediatric intensive care unit
* Has an underlying pre-existing condition that may affect the respiratory system (includes bronchopulmonary dysplasia, reactive airways disease, asthma, restrictive lung diseases, other chronic lung diseases, etc.)
* Has other comorbid conditions upon admission that may affect the respiratory system (includes pneumonia or other bacterial or fungal lung infections, acute exacerbation of reactive airways disease, acute exacerbation of asthma, pulmonary edema, pleural effusion, etc.)
* Has an absolute contraindication to nebulized 3% hypertonic saline, for example, a history of an allergic or anaphylactic reaction
* Is receiving other respiratory treatments such as bronchodilator treatments (i.e. albuterol or levalbuterol)
* Is receiving other adjuvant therapy such as antibiotics, antivirals, glucocorticoids, corticosteroids, or diuretics
The Effect of Repetitive Standardized Patient Simulation and End of Life Care Education on Nursing Students' Knowledge Attitudes and Moods

This research is a randomized experimental intervention study designed to examine the effect of repetitive standard patient-based education given to nursing students with end-of-life care education nursing on the level of knowledge, attitudes, and moods of the patient's care during the death process.

The research Sample of the study consisted of fourth-year nursing students who agreed to participate in the study (n=50). In the study, an end-of-life care nursing education program was applied to all students. In the second stage, the standard patient-based practice was performed once with the control group nursing students and twice with the intervention group students. In data collection, an end-of-life care nursing questionnaire, Frommelt attitude scale, positive-negative affect scale, and modified simulation effectiveness tool were used.

Eligibility Criteria:
Inclusion Criteria:

* Not having a course in which a four-year undergraduate education is unsuccessful,
* Not participating in the pilot study of the research
* To voluntarily agree to participate in the research.
* Being a fourth-year student in the Department of Nursing

Exclusion Criteria:

* Participating in the pilot study of the research
* Wanting to leave the research.
* Being a first, second and third-year student in the Department of Nursing
GastrOesophageal Tumor, Immune Microenvionnment (GOTIM)

This trial is a prospective, monocentric, non-therapeutic, interventional cohort study aiming to decipher the immune TME through standard neoadjuvant CT in resectable G/GEJ adenocarcinomas. This study will also longitudinally monitor MRD during neoadjuvant and adjuvant therapy.


Eligibility Criteria:
Inclusion Criteria:

* Male or female patient \> 18 years of age on day of signing informed consent.
* Histologically proven non-metastatic resectable gastric and gastroesophageal junction adenocarcinoma, Stage IB to III to be treated with standard neoadjuvant treatment.
* Surgery of primary tumor to be done at Centre Léon Bérard.
* Availability of archival FFPE tumor block from initial diagnosis with at least 20% of tumor cells.
* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1 or 2.
* Patient should understand, sign, and date the written voluntary informed consent form at the screening visit prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.
* Patients must be covered by a medical insurance.

Exclusion Criteria:

* Any condition contraindicated with blood sampling procedures required by the protocol.
* Known additional malignancy that is progressing or requires active treatment. Exceptions include adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer
* Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure.
* Pregnant or breast-feeding woman.
Stress Management Program

This study will test the immediate and long term (post 4 weeks of daily practice) effectiveness of two breathwork practices, cyclic sighing and box breathing, in comparison to hypnosis and an audiobook about stress, on psychological and physiological variables.


Eligibility Criteria:
Inclusion Criteria:

* Age 18 or older
* No contraindications to MRI imaging (like ferromagnetic metal in their body)

Exclusion Criteria:

* Pregnant or planning to get pregnant during study participation.
* Not able or willing to come to research location twice for MRI assessments
Fear of Hypoglycemia and Glycemic Variability

Subjects with type 1 diabetes are invited to provide usual blood glucose monitoring and a blood glucose profile (Pre/ post prandial Blood Glucose + Night Blood Glucose) on 3 occasions in a 2 week time period, in addition to the filling of 5 questionnaires including fear of hypoglycemia-2 questionnaire.

Subjects with type 1 diabetes are invited to provide usual blood glucose monitoring and a blood glucose profile (Pre/ post prandial Blood Glucose + Night Blood Glucose) on 3 occasions in a 2 week time period, in addition to the filling of questionnaires including fear of hypoglycemia-2 questionnaire.

Biobanking of urine/blood Collection of key medical informations by investigators

Questionnaires :

* socio-economic status
* Fear of hypoglycemia-2
* Anxiety Depression scale (HAD)
* Health survey (SF36, SF12)
* Satisfaction to treatment (DHP-18)
* Dutch Eating Behavior Questionnaire (DEBQ)
* Pittsburgh quality of sleep (PSQI)
* Blood Glucose diary

Eligibility Criteria:
Inclusion Criteria :

* type 1 diabetes
* at least 2 Blood Glucose monitoring daily
* on insulin for more than 5 years

Exclusion Criteria :

* not stable metabolic condition (infection, steroid therapy)
* below 3 months change in insulin treatment
* other clinical trial
* renal failure (eDFG below 30 ml/min/1.73 m²)
* Pregnancy and/or lactation
To Accurately Assess Lymph Node Response to NACT by Wire Localization of Clip-marked Lymph Nodes

The investigator developed this protocol to accurately assess lymph node response to neoadjuvant chemotherapy in clinical stage N1 (cN1) breast cancer patients. Accuracy of sentinel lymph node biopsy (SLNB) alone and in combination with the removal of wire-localized-clip-marked nodes will be analyzed. New model to predict lymph node pathological complete remission (pCR) so as to safely avoid axillary lymph node dissection in cN1 breast cancer patients is sought for.

The investigator developed this protocol to accurately assess lymph node response to neoadjuvant chemotherapy in cN1 breast cancer patients. In brief, pathologically proven positive axillary lymph node will be clip-marked before the initiation of neoadjuvant chemotherapy (NACT) and continuously monitored through out the course of chemotherapy with ultrasound. After the completion of neoadjuvant chemotherapy, a wire will be placed to localize the clip-marked node before surgery. During surgery, a standard sentinel lymph node biopsy will be performed as well as the removal of the wire localized node. Axillary lymph node dissection (ALND) will be performed in all participants. Accuracy of SLNB alone and in combination with the removal of wire-localized-clip-marked nodes will be analyzed. Axillary ultrasound and CT scan will be performed before and after neoadjuvant chemotherapy for all patients enrolled. By assessing clinical-pathological and imaging data acquired from this trial, the investigator look forward to developing a model to accurately predict lymph node pCR (AUC \>0.85) so as to safely avoid axillary lymph node dissection in cN1 breast cancer patients.

Eligibility Criteria:
Inclusion Criteria:

* between the age of 18 and 65
* Eastern Cooperative Oncology Group (ECOG) score 0 or 1
* pathologically proven positive axillary lymph node
* enough renal and liver function to sustain chemotherapy
* informed consent obtained

Exclusion Criteria:

* inflammatory breast cancer
* being pregnant or nursing
* neoadjuvant chemotherapy not planned
Caregivers of Children With Autism Spectrum Disorder

This study aims to examine the relationship between caregiving burden and physical activity, exercise self-efficacy, and perceived exercise benefits and barriers in caregivers of Caregivers of children with autism spectrum disorder (CwASD).The study population consisted of primary caregivers of a CwASD for at least 1 year. Caregiving burden was assessed using the Zarit Caregiver Burden Scale, physical activity using the International Physical Activity Questionnaire-Short form (IPAQ-SF), exercise self-efficacy using the Exercise Self-Efficacy Scale, and perceived exercise benefit using the Exercise Benefits/Barriers Scale. The relationship between caregiver burden and other parameters was analysed.


Eligibility Criteria:
Inclusion Criteria:

* Over 18 years of age,
* Caring for a CwASD for at least 1 year,
* The child with autism is 18 years old or younger,
* being an informal carer,
* The caregiver is the person with primary responsibility for the care of the CwASD in the family.

Exclusion Criteria:

* People over the age of 65,
* Those without a diagnosed chronic physical condition leading to disability,
* Those caring for more than one CwASD, another disabled person, an older adult or someone needing care
Transcutaneous Electric Nerve Stimulation in Sleep of Patients With Parkinson's Disease

Sleep disorders are among the non-motor signs more common in Parkinson's disease (PD). This case series evaluated the effects of Transcutaneous Electrical Nerve Stimulation (TENS) on acupoints in the self-assessment of sleep in 14 PD patients classified between stages 1 and 3 of Hoehn and Yahr original (HY). Patients were assessed using the Sleep Scale for Parkinson's Disease (PDSS) and subjected to treatment with eight TENS sessions on acupoints, with the current Burst. We used the paired sample t-test, considering p ≤ 0.05.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of idiopathic PD between stages 1 and 3 according to the original version of the Hoehn \& Yahr (HY) scale

Exclusion Criteria:

* Patients with Mini Mental State Examination (MMSE) lower than 18 points, with other associated neurological diseases and on medication for depression, anxiety, psychosis and sleep inducers.
Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec

The purpose of this study is to determine whether treatment with Selumetinib (AZD6244) (Hyd-Sulfate) in combination with Irinotecan as a second treatment in patients with K-ras or B-raf mutation will prevent tumor progression and prolong progression free survival.

A Dose Finding and Phase II Study of Selumetinib (AZD6244) (Hyd-Sulfate) in Combination with Irinotecan, in 2nd Line Patients with K-ras or B-raf Mutation Positive Advanced or Metastatic Colorectal Cancer

Eligibility Criteria:
Inclusion Criteria:

- Histological or cytological confirmation of advanced or metastatic colorectal cancer with available tissue and tumor sample confirmed as K-ras or B-raf mutation positive. Current failure of 1st line anti-cancer therapy with an oxaliplatin and bevacizumab based regimen or patients relapsing within 12 months of completing adjuvant FOLFOX .

Exclusion Criteria:

- Treatment within 14 days prior to first study treatment with conventional therapy or treatment within 28 days prior to first study treatment with an investigational drug Prior treatment with a MEK or B-raf inhibitor or any irinotecan-containing regimen Prior treatment with a MEK or B-raf inhibitor or any irinotecan-containing regimen
Ibuprofen Concentration in Cerebro Spinal Fluid (CSF) of Infants and Children

Ibuprofen, the active ingredient in Nurofen and Advil, is a commonly used drug in children. There is very limited data about Ibuprofen concentrations in the cerebro spinal fluid (CSF). The objective of the current study is to describe concentrations of ibuprofen in the CSF of infants and children after administration of ibuprofen. We will study infants presenting to the Emergency Department (ED) with fever who received ibuprofen. A complete sepsis workup including sampling of blood and CSF is conducted in cases of suspected meningitis. We will measure ibuprofen in the blood and CSF obtained during the sepsis workup. A better understanding of the pharmacokinetics of ibuprofen and its penetration into the CSF will unable us to suggest more accurate dosing guidelines, and to better predict the effects of this commonly used drug.


Eligibility Criteria:
Inclusion Criteria:

* Age: 3 month-18 years
* Rectal temperature \> 38.0OC or oral temperature \> 37.6 OC measured in the ED or at home.
* A sepsis work up is indicated
* At least one dose of Ibuprofen was given in the last 8 hours prior to lumbar puncture (LP)

Exclusion Criteria:

* Hypersensitivity to Ibuprofen
* Known metabolic disorder
* Known liver or kidney disease
* Hydrocephalus
* Informed consent could not be obtained from a legal guardian
Efficacy of Lianhua Qingwen in Treating Patients Infected With the Omicron Variant of the COVID-19

A retrospective analysis was conducted on patients infected with the Omicron variant of COVID-19 diagnosed from August 2022 to now. Patients were divided into observation groups and control groups according to whether or not oral Lianhua Qingwen granules were used. Through data analysis and follow-up, the effectiveness of Lianhua Qingwen in treating patients infected with the Omicron variant of COVID-19 was discussed.


Eligibility Criteria:
Inclusion Criteria:

* For patients infected with the Omicron variant, the diagnostic criteria are confirmed cases of COVID-19 and clinical classification according to the diagnostic criteria of Prevention and Control Protocol for COVID-19 (Trial Eighth Edition) issued by the National Health and Construction Commission.
* The clinical symptoms were classified as mild or ordinary.
* They have been vaccinated against the COVID-19.

Exclusion Criteria:

* Patients receiving antiviral or antibiotic drugs
* Severe and critical patients with COVID-19.
* Patients with chronic respiratory diseases, bacterial infections of the respiratory system, and other respiratory diseases affecting the study.
* Patients with serious primary diseases of the heart, brain, lung, liver, kidney, and hematopoietic systems, as well as mental diseases.
* Allergic reaction to Lianhua Qingwen granules.
* Excluded patients treated with the same drug as Lianhua Qingwen.